The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Surgical site infections and antimicrobial resistance remain major challenges globally
A key highlight will be Brenntag’s qualified amino acids portfolio
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Subscribe To Our Newsletter & Stay Updated
